Article ; Online: Transient inhibition of sodium-glucose cotransporter 2 after ischemia/reperfusion injury ameliorates chronic kidney disease.
JCI insight
2024 Volume 9, Issue 6
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin (Dapa), exhibited nephroprotective effects in patients with chronic kidney disease (CKD). We assessed the efficacy of short-term Dapa administration following acute kidney injury (AKI) in ... ...
Abstract | Sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin (Dapa), exhibited nephroprotective effects in patients with chronic kidney disease (CKD). We assessed the efficacy of short-term Dapa administration following acute kidney injury (AKI) in preventing CKD. Male Wistar rats were randomly assigned to Sham surgery, bilateral ischemia for 30 minutes (abbreviated as IR), and IR + Dapa groups. Daily treatment with Dapa was initiated just 24 hours after IR and maintained for only 10 days. Initially, rats were euthanized at this point to study early renal repair. After severe AKI, Dapa promptly restored creatinine clearance (CrCl) and significantly reduced renal vascular resistance compared with the IR group. Furthermore, Dapa effectively reversed the mitochondrial abnormalities, including increased fission, altered mitophagy, metabolic dysfunction, and proapoptotic signaling. To study this earlier, another set of rats was studied just 5 days after AKI. Despite persistent renal dysfunction, our data reveal a degree of mitochondrial protection. Remarkably, a 10-day treatment with Dapa demonstrated effectiveness in preventing CKD transition in an independent cohort monitored for 5 months after AKI. This was evidenced by improvements in proteinuria, CrCl, glomerulosclerosis, and fibrosis. Our findings underscore the potential of Dapa in preventing maladaptive repair following AKI, emphasizing the crucial role of early intervention in mitigating AKI long-term consequences. |
---|---|
MeSH term(s) | Animals ; Humans ; Male ; Rats ; Acute Kidney Injury/drug therapy ; Acute Kidney Injury/prevention & control ; Acute Kidney Injury/metabolism ; Glucose ; Rats, Wistar ; Renal Insufficiency, Chronic/drug therapy ; Reperfusion Injury/complications ; Reperfusion Injury/metabolism ; Sodium/metabolism ; Sodium-Glucose Transporter 2/drug effects ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Benzhydryl Compounds/pharmacology ; Benzhydryl Compounds/therapeutic use |
Chemical Substances | Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27) ; Sodium-Glucose Transporter 2 ; dapagliflozin (1ULL0QJ8UC) ; Sodium-Glucose Transporter 2 Inhibitors ; Benzhydryl Compounds |
Language | English |
Publishing date | 2024-02-22 |
Publishing country | United States |
Document type | Journal Article |
ISSN | 2379-3708 |
ISSN (online) | 2379-3708 |
DOI | 10.1172/jci.insight.173675 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.